U.S. pharma giant copyright scrapped two experimental weight loss drugs last year—a at the time-each day tablet, lotiglipron, as a consequence of elevated liver enzymes plus a 2 times-every day capsule, danuglipron, on account of sturdy Unwanted side effects—but CEO Albert Bourla has